{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T03:57:38Z","timestamp":1789444658739,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72061137006"],"award-info":[{"award-number":["72061137006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2305103"],"award-info":[{"award-number":["2022YFC2305103"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11677-w","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:14:13Z","timestamp":1760080453000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of vaccination on SARS-CoV-2 infections and long COVID symptoms: a cross-sectional study in China"],"prefix":"10.1186","volume":"25","author":[{"given":"Xiaolong","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"11677_CR1","unstructured":"World Health Organization. WHO coronavirus (COVID-19) dashboard. 2024. https:\/\/covid19.who.int\/. Accessed 06 May 2024."},{"issue":"1","key":"11677_CR2","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/s41392-023-01724-w","volume":"8","author":"D Ao","year":"2023","unstructured":"Ao D, He X, Liu J, Xu L. Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period. Signal Transduct Target Ther. 2023;8(1):466. https:\/\/doi.org\/10.1038\/s41392-023-01724-w.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"11677_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41541-022-00597-4","volume":"7","author":"F Zhao","year":"2022","unstructured":"Zhao F, Zai X, Zhang Z, Xu J, Chen W. Challenges and developments in universal vaccine design against SARS-CoV-2 variants. NPJ Vaccines. 2022;7(1):167. https:\/\/doi.org\/10.1038\/s41541-022-00597-4.","journal-title":"NPJ Vaccines"},{"issue":"3","key":"11677_CR4","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3390\/vaccines11030690","volume":"11","author":"A Farlow","year":"2023","unstructured":"Farlow A, Torreele E, Gray G, Ruxrungtham K, Rees H, Prasad S, et al. The future of epidemic and pandemic vaccines to serve global public health needs. Vaccines. 2023;11(3):690. https:\/\/doi.org\/10.3390\/vaccines11030690.","journal-title":"Vaccines"},{"issue":"10377","key":"11677_CR5","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/S0140-6736(23)00129-0","volume":"401","author":"Y Pan","year":"2023","unstructured":"Pan Y, Wang L, Feng Z, Xu H, Li F, Shen Y, et al. Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological and phylogenetic analysis. Lancet. 2023;401(10377):664\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(23)00129-0.","journal-title":"Lancet"},{"issue":"5","key":"11677_CR6","doi-asserted-by":"publisher","first-page":"968","DOI":"10.3390\/vaccines11050968","volume":"11","author":"Y He","year":"2023","unstructured":"He Y, Zhang F, Liu Y, Xiong Z, Zheng S, Liu W, et al. Clinical characteristics of mild patients with breakthrough infection of Omicron variant in China after relaxing the dynamic zero COVID-19 policy. Vaccines. 2023;11(5):968. https:\/\/doi.org\/10.3390\/vaccines11050968.","journal-title":"Vaccines"},{"issue":"4","key":"11677_CR7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.46234\/ccdcw2022.015","volume":"4","author":"J Liu","year":"2022","unstructured":"Liu J, Liu M, Liang W. The dynamic COVID-Zero strategy in China. China CDC Wkly. 2022;4(4):74\u20135. https:\/\/doi.org\/10.46234\/ccdcw2022.015.","journal-title":"China CDC Wkly"},{"key":"11677_CR8","doi-asserted-by":"publisher","first-page":"n1088","DOI":"10.1136\/bmj.n1088","volume":"373","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373:n1088. https:\/\/doi.org\/10.1136\/bmj.n1088.","journal-title":"BMJ"},{"issue":"1","key":"11677_CR9","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/s41467-023-37176-7","volume":"14","author":"D Cromer","year":"2023","unstructured":"Cromer D, Steain M, Reynaldi A, Schlub TE, Khan SR, Sasson SC, et al. Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis. Nat Commun. 2023;14(1):1633. https:\/\/doi.org\/10.1038\/s41467-023-37176-7.","journal-title":"Nat Commun"},{"issue":"4","key":"11677_CR10","doi-asserted-by":"publisher","first-page":"e236","DOI":"10.1016\/s2666-5247(22)00390-1","volume":"4","author":"ZR Yang","year":"2023","unstructured":"Yang ZR, Jiang YW, Li FX, Liu D, Lin TF, Zhao ZY, et al. Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials. Lancet Microbe. 2023;4(4):e236\u201346. https:\/\/doi.org\/10.1016\/s2666-5247(22)00390-1.","journal-title":"Lancet Microbe"},{"issue":"4","key":"11677_CR11","doi-asserted-by":"publisher","first-page":"e229317","DOI":"10.1001\/jamanetworkopen.2022.9317","volume":"5","author":"ZJ Madewell","year":"2022","unstructured":"Madewell ZJ, Yang Y, Longini IM Jr., Halloran ME, Dean NE. Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis. JAMA Netw Open. 2022;5(4):e229317. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.9317.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"11677_CR12","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1186\/s12879-023-08553-w","volume":"23","author":"X Jing","year":"2023","unstructured":"Jing X, Han M, Wang X, Zhou L. SARS-CoV-2 vaccine breakthrough infection in the older adults: a meta-analysis and systematic review. Bmc Infect Dis. 2023;23(1):577. https:\/\/doi.org\/10.1186\/s12879-023-08553-w.","journal-title":"Bmc Infect Dis"},{"issue":"3","key":"11677_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","volume":"21","author":"HE Davis","year":"2023","unstructured":"Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133\u201346. https:\/\/doi.org\/10.1038\/s41579-022-00846-2.","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"11677_CR14","doi-asserted-by":"publisher","first-page":"2220578","DOI":"10.1080\/22221751.2023.2220578","volume":"12","author":"J Cai","year":"2023","unstructured":"Cai J, Lin K, Zhang H, Xue Q, Zhu K, Yuan G, et al. A one-year follow-up study of systematic impact of long COVID symptoms among patients post SARS-CoV-2 omicron variants infection in Shanghai, China. Emerg Microbes Infect. 2023;12(2):2220578. https:\/\/doi.org\/10.1080\/22221751.2023.2220578.","journal-title":"Emerg Microbes Infect"},{"issue":"2","key":"11677_CR15","doi-asserted-by":"publisher","first-page":"2258232","DOI":"10.1080\/22221751.2023.2258232","volume":"12","author":"S Qin","year":"2023","unstructured":"Qin S, Li Y, Wang L, Zhao X, Ma X, Gao GF. Assessment of vaccinations and breakthrough infections after adjustment of the dynamic zero-COVID-19 strategy in China: an online survey. Emerg Microbes Infect. 2023;12(2):2258232. https:\/\/doi.org\/10.1080\/22221751.2023.2258232.","journal-title":"Emerg Microbes Infect"},{"issue":"10223","key":"11677_CR16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507\u201313. https:\/\/doi.org\/10.1016\/S0140-6736(20)30211-7.","journal-title":"Lancet"},{"key":"11677_CR17","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.csbj.2021.01.042","volume":"19","author":"S Qin","year":"2021","unstructured":"Qin S, Li W, Shi X, Wu Y, Wang C, Shen J, et al. 3044 cases reveal important prognosis signatures of COVID-19 patients. Comput Struct Biotechnol J. 2021;19:1163\u201375. https:\/\/doi.org\/10.1016\/j.csbj.2021.01.042.","journal-title":"Comput Struct Biotechnol J"},{"issue":"10360","key":"11677_CR18","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/S0140-6736(22)01656-7","volume":"400","author":"U Agrawal","year":"2022","unstructured":"Agrawal U, Bedston S, McCowan C, Oke J, Patterson L, Robertson C, et al. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales. Lancet. 2022;400(10360):1305\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(22)01656-7.","journal-title":"Lancet"},{"issue":"10332","key":"11677_CR19","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S0140-6736(22)00462-7","volume":"399","author":"T Nyberg","year":"2022","unstructured":"Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(22)00462-7.","journal-title":"Lancet"},{"issue":"7","key":"11677_CR20","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1001\/jama.2022.0470","volume":"327","author":"EK Accorsi","year":"2022","unstructured":"Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. Jama-J Am Med Assoc. 2022;327(7):639\u201351. https:\/\/doi.org\/10.1001\/jama.2022.0470.","journal-title":"Jama-J Am Med Assoc"},{"issue":"22","key":"11677_CR21","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1001\/jama.2022.7493","volume":"327","author":"KE Fleming-Dutra","year":"2022","unstructured":"Fleming-Dutra KE, Britton A, Shang N, Derado G, Link-Gelles R, Accorsi EK, et al. Association of prior BNT162b2 COVID-19 vaccination with symptomatic SARS-CoV-2 infection in children and adolescents during Omicron predominance. Jama-J Am Med Assoc. 2022;327(22):2210\u20139. https:\/\/doi.org\/10.1001\/jama.2022.7493.","journal-title":"Jama-J Am Med Assoc"},{"issue":"2","key":"11677_CR22","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1136\/thoraxjnl-2021-216949","volume":"77","author":"P Hedberg","year":"2022","unstructured":"Hedberg P, Karlsson Valik J, van der Werff S, Tanushi H, Requena Mendez A, Granath F, et al. Clinical phenotypes and outcomes of SARS-CoV-2, influenza, RSV and seven other respiratory viruses: a retrospective study using complete hospital data. Thorax. 2022;77(2):154\u201363. https:\/\/doi.org\/10.1136\/thoraxjnl-2021-216949.","journal-title":"Thorax"},{"key":"11677_CR23","doi-asserted-by":"publisher","unstructured":"Danza P, Koo TH, Haddix M, Fisher R, Traub E, K OY, et al. SARS-CoV-2 infection and hospitalization among adults aged >\/=18 years, by vaccination status, before and during SARS-CoV-2 B.1.1.529 (Omicron) variant predominance - Los Angeles county, California, November 7, 2021-January 8, 2022. MMWR Morbidity and mortality weekly report 2022;71(5):177\u2013181. https:\/\/doi.org\/10.15585\/mmwr.mm7105e1.","DOI":"10.15585\/mmwr.mm7105e1"},{"issue":"7","key":"11677_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.15585\/mmwr.mm7107e2","volume":"71","author":"JM Ferdinands","year":"2022","unstructured":"Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION network, 10 states, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(7):255\u201363. https:\/\/doi.org\/10.15585\/mmwr.mm7107e2.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"11677_CR25","doi-asserted-by":"publisher","first-page":"e2228900","DOI":"10.1001\/jamanetworkopen.2022.28900","volume":"5","author":"OT Ng","year":"2022","unstructured":"Ng OT, Marimuthu K, Lim N, Lim ZQ, Thevasagayam NM, Koh V, et al. Analysis of COVID-19 incidence and severity among adults vaccinated with 2-dose mRNA COVID-19 or inactivated SARS-CoV-2 vaccines with and without boosters in Singapore. JAMA Netw Open. 2022;5(8):e2228900. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.28900.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"11677_CR26","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1093\/infdis\/jiac161","volume":"226","author":"M Smid","year":"2022","unstructured":"Smid M, Berec L, Pribylova L, Majek O, Pavlik T, Jarkovsky J, et al. Protection by vaccines and previous infection against the Omicron variant of Severe Acute Respiratory Syndrome Coronavirus 2. J Infect Dis. 2022;226(8):1385\u201390. https:\/\/doi.org\/10.1093\/infdis\/jiac161.","journal-title":"J Infect Dis"},{"key":"11677_CR27","doi-asserted-by":"publisher","first-page":"940562","DOI":"10.3389\/fimmu.2022.940562","volume":"13","author":"W Kulper-Schiek","year":"2022","unstructured":"Kulper-Schiek W, Piechotta V, Pilic A, Batke M, Dreveton LS, Geurts B, et al. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review. Front Immunol. 2022;13:940562. https:\/\/doi.org\/10.3389\/fimmu.2022.940562.","journal-title":"Front Immunol"},{"key":"11677_CR28","doi-asserted-by":"publisher","first-page":"1150095","DOI":"10.3389\/fpubh.2023.1150095","volume":"11","author":"C Zhou","year":"2023","unstructured":"Zhou C, Wheelock AM, Zhang C, Ma J, Dong K, Pan J, et al. The role of booster vaccination in decreasing COVID-19 age-adjusted case fatality rate: evidence from 32 countries. Front Public Health. 2023;11:1150095. https:\/\/doi.org\/10.3389\/fpubh.2023.1150095.","journal-title":"Front Public Health"},{"issue":"1","key":"11677_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jama.2021.8565","volume":"326","author":"N Al Kaabi","year":"2021","unstructured":"Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326(1):35\u201345. https:\/\/doi.org\/10.1001\/jama.2021.8565.","journal-title":"JAMA"},{"issue":"140","key":"11677_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ijid.2023.11.038","volume":"3","author":"D Salmon","year":"2024","unstructured":"Salmon D, Slama D, Linard F, Dumesges N, Le Baut V, Hakim F, et al. Patients with Long COVID continue to experience significant symptoms at 12 months and factors associated with improvement: A prospective cohort study in France (PERSICOR). Int J Infect Dis. 2024;3(140):9\u201316. https:\/\/doi.org\/10.1016\/j.ijid.2023.11.038.","journal-title":"Int J Infect Dis"},{"issue":"2","key":"11677_CR31","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41423-023-01095-w","volume":"21","author":"D Lapuente","year":"2024","unstructured":"Lapuente D, Winkler TH, Tenbusch M. B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity. Cell Mol Immunol. 2024;21(2):144\u201358. https:\/\/doi.org\/10.1038\/s41423-023-01095-w.","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"11677_CR32","doi-asserted-by":"publisher","first-page":"e0001917","DOI":"10.1371\/journal.pgph.0001917","volume":"3","author":"M De Domenico","year":"2023","unstructured":"De Domenico M. Prevalence of long COVID decreases for increasing COVID-19 vaccine uptake. PLOS Glob Public Health. 2023;3(6):e0001917. https:\/\/doi.org\/10.1371\/journal.pgph.0001917.","journal-title":"PLOS Glob Public Health"},{"issue":"5","key":"11677_CR33","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3390\/vaccines10050652","volume":"10","author":"WD Strain","year":"2022","unstructured":"Strain WD, Sherwood O, Banerjee A, Van der Togt V, Hishmeh L, Rossman J. The impact of COVID vaccination on symptoms of long COVID: an international survey of people with lived experience of long COVID. Vaccines. 2022;10(5):652. https:\/\/doi.org\/10.3390\/vaccines10050652.","journal-title":"Vaccines"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11677-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11677-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11677-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T11:24:32Z","timestamp":1760354672000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11677-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11677"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11677-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"18 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study performed in accordance with the Declaration of Helsinki. The study protocol was approved by the Clinical Research Review Board of Huazhong University of Science and Technology Tongji Medical College (registration number: 2021-IEC-A209). All participants signed an informed consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1266"}}